Our Partners

UMN Pharma: is a pharmaceutical company dedicated to developing innovative pharmaceutical products that will satisfy unmet medical needs. UMN has exclusively licensed FluBlok and PanBlok for the territory of Japan. UMN is actively conducting clinical trials and constructing a manufacturing facility in Japan to support commercialization of the vaccine candidates.

Diamyd Medical: Diamyd is a biopharmaceutical company in the field of diabetes and has partnered with Protein Sciences as a commercial manufacturer of their diabetes vaccine candidate Diamyd® which has entered Phase III clinical development.

Nosan Corporation: of Japan has partnered with Protein Sciences to distribute the Research Products and provide GeneXpress services to the Japanese marketplace.

AMT: AMT has become a leader in the field of human gene therapy using rAAV vectors and has licensed PSC's technology to commercialize therapies of severe (orphan) diseases.

Boehringer Ingelheim: Boehringer Ingelheim Animal Health has a wide range of products for the successful treatment for animals.

Tissue Therapies: Tissue Therapies provides wound healing, tissue repair and cell culture technology through a novel growth factor platform technology, VitroGro®.

Bellicum Pharmaceuticals: Bellicum Pharmaceuticals is focused primarily on the development of next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer.

Oxford Expression Technologies: Oxford Expression Technologies (OET) is a centre of expertise for recombinant protein production using the baculovirus expression vector system. OET is working with Protein Sciences to offer complementary expertise in the use of BEVS."